Vasomotor Symptom Characteristics: Are They Risk Factors for Incident Diabetes?

Overview

Journal Menopause

Specialty Gynecology & Obstetrics

Date 2017 Dec 6

PMID 29206771

Citations 17

Authors

Kristen E Gray

Jodie G Katon

Erin S LeBlanc

Nancy F Woods

Lori A Bastian

Gayle E Reiber

Julie C Weitlauf

Karin M Nelson

Andrea Z LaCroix

Affiliations

Soon will be listed here.

Abstract

Objective: Vasomotor symptoms (VMS), encompassing hot flashes and night sweats, may be associated with diabetes, but evidence is limited. We sought to estimate these associations.

Methods: Among 150,007 postmenopausal Women's Health Initiative participants from 1993 to 2014, we prospectively examined associations of incident diabetes with VMS characteristics at enrollment: any VMS, severity (mild/ moderate/severe), type (hot flashes/night sweats), timing (early [premenopausal or perimenopausal]/late [postmenopausal]), and duration. Cox proportional-hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs).

Results: Mean duration of follow-up was 13.1 years. VMS prevalence was 33%. Reporting any VMS was associated with 18% increased diabetes risk (95% CI 1.14, 1.22), which increased with severity (mild: HR 1.13, 95% CI 1.08, 1.17; moderate: HR 1.29, 95% CI 1.22, 1.36; severe: HR 1.48, 95% CI 1.34, 1.62) and duration (4% per 5 years, 95% CI 1.03, 1.05), independent of obesity. Diabetes risk was more pronounced for women reporting any night sweats (night sweats only: HR 1.20, 95% CI 1.13, 1.26; night sweats and hot flashes: HR 1.22, 95% CI 1.17, 1.27) than only hot flashes (HR 1.08, 95% CI 1.02, 1.15) and was restricted to late VMS (late: HR 1.12, 95% CI 1.07, 1.18; early and late: HR 1.16, 95% CI 1.11, 1.22; early: HR 0.99, 95% CI 0.95, 1.04).

Conclusions: VMS are associated with elevated diabetes risk, particularly for women reporting night sweats and postmenopausal symptoms. The menopause transition may be an optimal window for clinicians to discuss long-term cardiovascular/metabolic risk with patients and leverage the bother of existing symptoms for behavior change to improve VMS and reduce diabetes risk.

Citing Articles

A Systematic Review of Anxiety and Depressive Symptoms Among Women Experiencing Vasomotor Symptoms Across Reproductive Stages in the US.

Gibson C, Ajmera M, OSullivan F, Shiozawa A, Lozano-Ortega G, Badillo E Int J Womens Health. 2025; 17:537-552.

PMID: 40034973 PMC: 11874770. DOI: 10.2147/IJWH.S491640.

Vasomotor Symptom Trajectories and Risk of Incident Diabetes.

Hedderson M, Liu E, Lee C, El Khoudary S, Gold E, Derby C JAMA Netw Open. 2024; 7(10):e2443546.

PMID: 39480425 PMC: 11528338. DOI: 10.1001/jamanetworkopen.2024.43546.

Menopausal Hormone Therapy in Women with Type 2 Diabetes Mellitus: An Updated Review.

Paschou S, Athanasiadou K, Papanas N Diabetes Ther. 2024; 15(4):741-748.

PMID: 38363540 PMC: 10951155. DOI: 10.1007/s13300-024-01546-1.

Reproductive risk factors across the female lifecourse and later metabolic health.

Nichols A, Chavarro J, Oken E Cell Metab. 2024; 36(2):240-262.

PMID: 38280383 PMC: 10871592. DOI: 10.1016/j.cmet.2024.01.002.

Menopause Is More Than Just Loss of Fertility.

Baker C, Benayoun B Public Policy Aging Rep. 2023; 33(4):113-119.

PMID: 38155935 PMC: 10751372. DOI: 10.1093/ppar/prad023.

References

. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015; 3(11):866-75. PMC: 4623946. DOI: 10.1016/S2213-8587(15)00291-0. View

Tuomikoski P, Ylikorkala O, Mikkola T . Menopausal hot flashes and insulin resistance. Menopause. 2012; 19(10):1116-20. DOI: 10.1097/gme.0b013e3182503d5d. View

Szmuilowicz E, Manson J, Rossouw J, Howard B, Margolis K, Greep N . Vasomotor symptoms and cardiovascular events in postmenopausal women. Menopause. 2011; 18(6):603-10. PMC: 3123435. DOI: 10.1097/gme.0b013e3182014849. View

Gold E, Colvin A, Avis N, Bromberger J, Greendale G, Powell L . Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health. 2006; 96(7):1226-35. PMC: 1483882. DOI: 10.2105/AJPH.2005.066936. View

Pan A, Schernhammer E, Sun Q, Hu F . Rotating night shift work and risk of type 2 diabetes: two prospective cohort studies in women. PLoS Med. 2011; 8(12):e1001141. PMC: 3232220. DOI: 10.1371/journal.pmed.1001141. View

Cappuccio F, DElia L, Strazzullo P, Miller M . Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2009; 33(2):414-20. PMC: 2809295. DOI: 10.2337/dc09-1124. View

Jackson J, DeFor T, Crain A, Kerby T, Strayer L, Lewis C . Validity of diabetes self-reports in the Women's Health Initiative. Menopause. 2014; 21(8):861-8. PMC: 4278641. DOI: 10.1097/GME.0000000000000189. View

. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials. 1998; 19(1):61-109. DOI: 10.1016/s0197-2456(97)00078-0. View

Brancati F, Kao W, Folsom A, Watson R, Szklo M . Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA. 2000; 283(17):2253-9. DOI: 10.1001/jama.283.17.2253. View

10.

Kanaya A, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V . Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003; 138(1):1-9. DOI: 10.7326/0003-4819-138-1-200301070-00005. View

11.

Moline M, Broch L, Zak R, Gross V . Sleep in women across the life cycle from adulthood through menopause. Sleep Med Rev. 2003; 7(2):155-77. DOI: 10.1053/smrv.2001.0228. View

12.

Margolis K, Bonds D, Rodabough R, Tinker L, Phillips L, Allen C . Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004; 47(7):1175-1187. DOI: 10.1007/s00125-004-1448-x. View

13.

Whiteman M, Staropoli C, Langenberg P, McCarter R, Kjerulff K, Flaws J . Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol. 2003; 101(2):264-72. DOI: 10.1016/s0029-7844(02)02593-0. View

14.

Appiah D, Winters S, Hornung C . Bilateral oophorectomy and the risk of incident diabetes in postmenopausal women. Diabetes Care. 2013; 37(3):725-33. DOI: 10.2337/dc13-1986. View

15.

Maxwell S, Cole D . Bias in cross-sectional analyses of longitudinal mediation. Psychol Methods. 2007; 12(1):23-44. DOI: 10.1037/1082-989X.12.1.23. View

16.

Hays J, Hunt J, Hubbell F, Anderson G, Limacher M, Allen C . The Women's Health Initiative recruitment methods and results. Ann Epidemiol. 2003; 13(9 Suppl):S18-77. DOI: 10.1016/s1047-2797(03)00042-5. View

17.

Herber-Gast G, Brown W, Mishra G . Hot flushes and night sweats are associated with coronary heart disease risk in midlife: a longitudinal study. BJOG. 2014; 122(11):1560-7. DOI: 10.1111/1471-0528.13163. View

18.

Roche M, Wang P . Sex differences in all-cause and cardiovascular mortality, hospitalization for individuals with and without diabetes, and patients with diabetes diagnosed early and late. Diabetes Care. 2013; 36(9):2582-90. PMC: 3747934. DOI: 10.2337/dc12-1272. View

19.

Stuenkel C . Is it WISE to link vasomotor symptoms with cardiovascular disease?. Menopause. 2017; 24(2):121-123. DOI: 10.1097/GME.0000000000000826. View

20.

Thurston R, Joffe H . Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. Obstet Gynecol Clin North Am. 2011; 38(3):489-501. PMC: 3185243. DOI: 10.1016/j.ogc.2011.05.006. View